Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Leukemia, Myelomonocytic, Acute 4Leukemia, Myeloid, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Lymphoma, Non-Hodgkin 3Wilms Tumor 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Melanoma 2Medulloblastoma 2Leukemia, Myelomonocytic, Chronic 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Head and Neck Neoplasms 2Glioma 2Glioblastoma 2Ependymoma 2Congenital Abnormalities 2Breast Neoplasms 2Brain Neoplasms 2Anemia, Refractory, with Excess of Blasts 2Xanthogranuloma, Juvenile 1

Interventions

Carboplatin 235Pemetrexed 214Paclitaxel 160Cisplatin 150pembrolizumab 145Erlotinib Hydrochloride 141Docetaxel 133Gemcitabine 94Bevacizumab 85Nivolumab 72Radiotherapy 62atezolizumab 40Radiosurgery 37Afatinib 37osimertinib 35130-nm albumin-bound paclitaxel 35Cetuximab 34durvalumab 33Ipilimumab 32Gefitinib 31Albumin-Bound Paclitaxel 29Vinorelbine 23Taxes 22Etoposide 20Crizotinib 19Radiation 17Sorafenib 16Cyclophosphamide 16Dexamethasone 15Magnetic Resonance Spectroscopy 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Non-Small-Cell Lung × tipifarnib × Clear all
NCT03496766 2025-03-05

Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS

Spanish Lung Cancer Group

Phase 2 Terminated
9 enrolled 22 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡